<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689702</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62202-688</org_study_id>
    <nct_id>NCT00689702</nct_id>
  </id_info>
  <brief_title>Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer</brief_title>
  <acronym>XERT</acronym>
  <official_title>Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added
      to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced
      primary resectable rectal cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative radiotherapy and 5-FU based chemotherapy, along with the complete resection of
      the mesorectum is a standard treatment of locally advanced rectal cancer.Capecitabine has the
      potential to replace 5-FU as standard agent. Cetuximab is a monoclonal antibody directed
      against EGFR. Both agents are active in treatment of colorectal cancer and have demonstrated
      radiosensitising properties.The trial aims to assess the efficacy, safety and toxicity of the
      combination of cetuximab, capecitabine and radiation in patients with stage II and III rectal
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete pathological remission rate</measure>
    <time_frame>at pathological examm of surgical speciment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of sphincter sparing surgical procedure Toxicity/safety</measure>
    <time_frame>Toxicity/safety:during preoperative treatment, early and late postoperative follow up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab, capecitabine</intervention_name>
    <description>Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).
Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.
Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks.</description>
    <other_name>Erbitux</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 80 if judged fit for surgery

          -  WHO performance status 0-1

          -  Histologically proven rectal adenocarcinoma located below the peritoneum

          -  T3-T4 or/and nodal involvement determined by rectal ultrasound or computed tomography
             (CT) or MRI

          -  No distant metastases

          -  Adequate haematological, cardiac, liver and renal function

          -  Signed informed consent

          -  Appropriate measures for contraception for men and women, if applicable

        Exclusion Criteria:

          -  Prior radio- and/or chemotherapy

          -  Others synchronous cancers

          -  History of other malignant disease

          -  Significant heart disease

          -  Known hypersensitivity to biological drugs

          -  Pregnant or lactating patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaneja Velenik, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Oncology, Ljubljana, Slovenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53.</citation>
    <PMID>15913913</PMID>
  </reference>
  <reference>
    <citation>Grünwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol. 2003;532:235-46. Review.</citation>
    <PMID>12908562</PMID>
  </reference>
  <reference>
    <citation>Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006 Oct;47(5):693-700.</citation>
    <PMID>17042060</PMID>
  </reference>
  <reference>
    <citation>Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001 Jul 1;19(13):3234-43.</citation>
    <PMID>11432891</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Vaneja Velenik, PhD, MD,</name_title>
    <organization>Institute of Oncology Ljubljana, Slovenia</organization>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>capecitabine</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

